Search Results
Your search for ,HOW matches 8289 pages
Showing 4951 - 5000For the Impoverished, Health Care Is a Luxury
Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...
FDA Approves Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) today approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) whose tumors express the CD33 antigen. The drug was also approved for the treatment of patients aged 2 years and older with...
ASCO Publishes Resources for Cancer Care Providers and Patients Affected by Hurricane Harvey
In the aftermath of the devastation caused by Hurricane Harvey throughout the state of Texas, which has resulted in more than 30,000 people being displaced from their homes, ASCO has published a list of resources and information for oncology providers and patients with cancer affected by the...
Artificial Intelligence May Help With Earlier Detection of Skin Cancer
New technology being developed by researchers at the University of Waterloo and the Sunnybrook Research Institute is using artificial intelligence (AI) to help detect melanoma at earlier stages. The technology employs machine-learning software to analyze images of skin lesions and provide...
Association of Systemic Inflammation and Sarcopenia With Survival in Early-Stage Colorectal Cancer
Results from the C SCANS (Colorectal Cancer: Sarcopenia, Cancer, and Near-Term Survival) study indicate that prediagnosis systemic inflammation and at-diagnosis sarcopenia are associated with an increased mortality risk in patients with nonmetastatic colorectal cancer. The findings were reported in ...
Concurrent Treatment With OX40 Agonist Antibody and PD-1 Blockade
Although the potential for immunotherapy to improve outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, is becoming increasingly evident, how to optimally combine the many new immunotherapy agents being developed remains a major...
Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...
Comparison of Screening Recommendations for Mammography
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening...
Chi Van Dang, MD, PhD, Appointed Professor at the Wistar Institute
THE WISTAR INSTITUTE has announced the appointment of scientist, medical oncologist, and National Academy of Medicine member Chi Van Dang, MD, PhD, as Professor. Dr. Dang, the Scientific Director of the Ludwig Institute for Cancer Research in New York, shapes scientific strategy at Ludwig, as...
Resource for Your Patients on Weight Management
ASCO’S BOOKLET Managing Your Weight After a Cancer Diagnosis: A Guide for Patients and Families addresses how being obese or overweight can slow recovery and affect survival. Readers will find information on different weight loss methods, common challenges to losing weight and maintaining weight...
Liquid Biopsies Identify Distinct Genomic Profiles With Potentially Targetable Alterations in Carcinoma of Unknown Primary
Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7% of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published by Kato et al in Cancer Research....
Team Aims to Apply CAR T-Cell Therapy to Pancreatic Cancer
STAND UP TO CANCER (SU2C) and Lustgarten Foundation for Pancreatic Cancer Research are supporting a new translational research team to explore how chimeric antigen receptor (CAR) T-cell therapy can be applied to pancreatic cancer. The approach uses specially modified immune cells to find and...
International Consensus (or Not) on Management of Advanced Prostate Cancer
ALTHOUGH THE National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly influence the management of advanced prostate cancer, they do not always reflect actual clinical practice. It turns out that in the real world, there are multiple areas ...
Updates of Key Trials in Metastatic Non–Small Cell Lung Cancer: KEYNOTE-024 and AvaALL
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of Thoracic Medical...
Fighting Misinformation in HPV-Related Cancer Prevention
FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since 2006...
Reuben Shaw, PhD, Receives NCI Outstanding Investigator Award
Salk Institute for Biological Studies Professor Reuben Shaw, PhD, has received the National Cancer Institute (NCI) Outstanding Investigator Award, which encourages cancer research with breakthrough potential. Dr. Shaw, a member of Salk’s Molecular and Cell Biology Laboratory and holder of the...
Look for Opportunities to Lower Barriers to Participation of Older Patients in Oncology Clinical Trials
Practicing evidence-based medicine requires evidence, but the evidence for efficacy and safety of new and evolving cancer therapies in older adults is wanting due to their underrepresentation in oncology clinical trials. “It is difficult to practice evidence-based medicine in an older population...
‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, FACP, FASCO, noted in an interview with The ASCO Post. Prompting those changes are...
A Personal Tribute to Angela H. Brodie, PhD, a Scientist Who Transformed Breast Cancer Treatment
Angela H. Brodie, PhD, a pioneer in breast cancer research, passed away on June 7, 2017, from complications of Parkinson’s disease and pancreatic cancer. An obituary for Dr. Brodie was published previously in the June 25, 2017, issue of The ASCO Post. Here, Dr. Balkees Abderrahman shares a...
Robert L. Ferris, MD, PhD, Named Director of UPMC Hillman Cancer Center
Robert L. Ferris, MD, PhD, an expert in immunotherapy and a specialist in head and neck cancer, has been named Director of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. His appointment was effective July 1. Dr. Ferris, a 15-year veteran of the UPMC Hillman Cancer...
Making Our Future Plans Happen Now
The following essay by Hope S. Rugo, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I was in...
Unraveling the Complexities of Cellular Immunotherapy and Its Potential to Cure Some Cancers
This past fall, the Fred Hutchinson Cancer Research Center in Seattle opened an all-encompassing 9,222-square foot outpatient cellular immunotherapy clinic, specifically designed to serve patients participating in the center’s novel immunotherapy clinical trials, which mainly focus on chimeric...
Clinical Trials Actively Recruiting Patients With Stage II/III Colorectal Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with stage II or III colorectal cancer. These studies highlight dietary intervention, supplements, immunotherapy, combination chemotherapy, neoadjuvant therapy, and...
Triple-Negative Breast Cancer: Practical Approach, Promising Research
Triple-negative breast cancer has a reputation for being a particularly challenging malignancy, but breast cancer specialist Nancy Davidson, MD, Senior Vice President of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Seattle, put this in perspective in a recent...
FDA to Expand Public Education Campaign to Focus on Prevention of Youth E-Cigarette Use
On August 8, the U.S. Food and Drug Administration (FDA) announced it would pursue a strategic, new public health education campaign aimed at discouraging the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) by children. The agency plans to expand its “The Real...
ASCO Resource to Help Your Patients Quit Tobacco
ASCO’s patient booklet Stopping Tobacco Use After a Cancer Diagnosis offers people with cancer and their caregivers information on why and how to quit tobacco use. With information on available treatments and resources, this booklet gives patients the practical tools to work with their health-care...
Don’t Miss Your Chance to Participate in the 2017 ASCO Practice Census
There is less than 1 month left to participate in this year’s ASCO Practice Census— the only annual survey of the entire U.S. oncology practice community that aims to identify changes in cancer care and oncology practice over time. It is crucial that practices in all settings across the United...
Practice Engagement Program Connects Practices to Resources to Adapt to Health-Care Changes
ASCO launched its Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. The Practice Engagement...
ASCO President Bruce E. Johnson Seeks to Bring Personalized Medicine, Real-Time Data to Every Oncology Practice
Dedicating one’s career and livelihood to the pursuit of treating and possibly curing cancer is, for many, a decision that stems from deeply personal and, often, tragic experience. For 2017–2018 ASCO President Bruce E. Johnson, MD, FASCO, the event that greatly influenced his decision was the...
Cancer at Baseline Screening in Patients With Li-Fraumeni Syndrome
In a new study from the National Cancer Institute (NCI), researchers found a higher-than-expected prevalence of cancer at baseline screening in individuals with Li-Fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain cancers. The research demonstrates...
Patients With Advanced Cancer Presenting to Emergency Departments With Delirium Likely to Die Earlier
According to a new study published by Elsayem et al in The Oncologist, patients with advanced cancer who are diagnosed with delirium when presenting to emergency departments are more likely to be hospitalized and more likely to die earlier than patients without delirium. This shows the importance...
ASCO Tackles the Issue of the High Cost of Cancer Drugs
In July, ASCO issued a comprehensive set of recommendations to remedy the problem of escalating drug pricing on cancer therapies.1 ASCO’s position statement comes at a time when new cancer drugs are routinely priced at $100,000 a year or more—imatinib (Gleevec) costs up to $146,000 a year2—causing...
Fox Chase Announces New Immunotherapy Trial in Breast Cancer
PATIENTS WITH SOME TYPES of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase II immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing ...
Sylvia
The following essay by Howard A. (Skip) Burris III, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org....
FDA Announces Comprehensive Regulatory Plan to Shift Trajectory of Tobacco-Related Disease, Death
On July 28, the U.S. Food and Drug Administration (FDA) announced a new comprehensive plan for tobacco and nicotine regulation that will serve as a multiyear roadmap to better protect children and significantly reduce tobacco-related disease and death. The approach places nicotine and the issue of...
Roswell Park Graduate Student Honored by National Cancer Institute
Roswell Park Cancer Institute graduate student Danielle Twum has received the prestigious Emerging Scholars Award from the National Cancer Institute (NCI), who recognized her among the distinguished alumni of its Continuing Umbrella for Research Excellence (CURE) programs. The CURE programs are...
An Expert on End-of-Life Care Shares Her Stories
“In the sufferer let me see only the human being.” So said Maimonides, the medieval Jewish philosopher and physician who espoused treating the patient rather than the illness, a philosophy that modern oncology had to relearn. This brief quote greets readers of a new book called Extreme Measures:...
A Deep and Incisive Look Into the Health-Care System
The seemingly impossible-to-cure maladies of our $3 trillion per year health-care system have been hyperanalyzed, fiercely debated, and voluminously written about by the country’s leading public health experts, opinionated doctors, and policymakers on Capitol Hill. The Affordable Care Act extended ...
A Textbook That Fills a Special Need in Oncology: Uncommon Cancers
A cancer diagnosis provokes a sea of emotions, fear and anxiety over the future foremost. However, being diagnosed with a common cancer such as breast or prostate cancer has a hard-won comfort zone, in that both patients and physicians are armed with a plethora of data and resources on how to treat ...
I Live My Life in 3- to 6-Month Increments
I first noticed a lump in my left breast in 2001 while taking a shower and shrugged it off. After all, men don’t get breast cancer. To assuage my wife’s concern that I at least have the lump examined, I consented to see our family physician, who agreed that men don’t get breast cancer because, he...
Searching for Happiness
This is the story, told through their own photographs, of a group of adolescent patients with cancer in their search for happiness. Their images relay their hopes and fears, their desire to be normal, and their urge to escape. These photographs are the outcome of a creative arts–based support...
How to Help Young Patients Preserve Their Fertility
GUEST EDITOR Adolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon Hayes-Lattin, MD, FACP, Professor of Medicine and Medical Director...
Breast Cancer Surveillance Consortium Receives $17 Million NCI Grant
INVESTIGATORS AT Breast Cancer Surveillance Consortium (BCSC) have received a $17 million program project grant renewal from the National Cancer Institute to study the effectiveness of different breast cancer screening and surveillance strategies using digital mammography, digital breast...
One Size May Not Fit All: Thoughts on the New Adjuvant Bisphosphonate Guideline for Early-Stage Breast Cancer
The oncology community has now conducted several prospectively designed, hypothesis-driven randomized clinical trials among women with breast cancer to address this question: Do adjuvant bisphosphonates decrease the risk of breast cancer bone metastases and other recurrence? A meta-analysis1 by...
Advances in the Treatment of Triple-Negative Breast Cancer
WITHIN THE SPECTRUM of breast cancer subtypes, triple-negative disease is “particularly troubling,” but better scientific understanding of this malignancy is leading to advances in its treatment, according to breast cancer expert Nancy Davidson, MD. Triple-negative breast cancer does not express...
Financial Toxicity: Cancer Supportive Care Professionals Consider the Side Effects of Soaring Costs
IS IT POSSIBLE to identify patients with cancer who are at risk for financial stress and intervene to reduce that risk? And could reducing financial stress—or financial toxicity, as it is often called in the context of cancer care—improve both health-related quality of life and physical health?...
FDA’s First Site-Agnostic Drug Approval Marks a Paradigm Shift in Regulatory Criteria
IN MAY, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with solid tumors that have the microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) biomarker, which disrupts the ability of cells to repair DNA. The...
A New Triumvirate in Estrogen Receptor–Positive Metastatic Breast Cancer
THE BODY OF EVIDENCE supporting the use of cell-cycle inhibitors in combination with endocrine therapy for estrogen receptor–positive metastatic breast cancer now has another agent in the spotlight. The phase III MONARCH 2 trial—reported at the 2017 ASCO Annual Meeting and by Sledge et al in the...
An Educational Program for Safe Handling of Opioids
Improper storage, use, and disposal of prescribed opioids can lead to diversion or accidental overdose. Given that opioids are the mainstay of cancer pain treatment, this issue is particularly germane in the oncology community. The ASCO Post recently spoke with Akhila Reddy, MD, and Maxine de la...
First Oncologist Elected AMA President, Barbara L. McAneny, MD, Advocates for Access to Health Care for Everyone
Since the founding of the American Medical Association (AMA) in 1847, Barbara L. McAneny, MD, is the fourth woman and first oncologist to be elected President of the venerable medical association. “I’m a generic Midwesterner. I was born in Missouri and raised in Madison County, Illinois, and went...
